Effect of postconditioning on infarct size in patients with ST elevation myocardial infarction.
BACKGROUND
Small studies suggest that postconditioning reperfusion interrupted by brief repetitive cycles of reocclusions, may protect the myocardium in the clinical setting.


OBJECTIVE
To test the hypothesis that postconditioning limits infarct size in relation to the area at risk in patients with ST elevation myocardial infarction (STEMI).


METHODS
76 patients (aged 37-87&emsp14;years) eligible for primary percutaneous coronary intervention due to STEMI were randomised to standard percutaneous coronary intervention (n = 38) or postconditioning, consisting of four cycles of 60 s reperfusion and 60 s of reocclusion before permanent reperfusion (n = 38).


RESULTS
The area at risk was determined from angiographic abnormally contracting segments. Infarct size was quantified from delayed enhancement MRI on days 6-9. Infarct size, expressed in relation to the area at risk, did not differ between the control group (44%; 30, 56) (median and quartiles) and the post-conditioned group (47%; 23, 63). The slope of the regression lines relating infarct size to the area at risk differed between the two groups. Infarct size was significantly (p = 0.001) reduced by postconditioning in patients with large areas at risk. The area under the curve and peak troponin T release and CKMB during 48&emsp14;h did not differ between patients in the control and postconditioning groups.


CONCLUSIONS
This prospective, randomised trial suggests that postconditioning does not reduce infarct size in patients with STEMI in the overall study group. The data indicate that postconditioning may be of value in patients with large areas at risk. Clinical trial registration information Karolinska Clinical Trial Registration (http://www.kctr.se). Unique identifier: CT20080014.
Sörensson
Peder
P
Karolinska University Hospital, 171 76 Stockholm, Sweden. peder.sorensson@karolinska.se
Saleh
Nawzad
N
Bouvier
Frederic
F
Böhm
Felix
F
Settergren
Magnus
M
Caidahl
Kenneth
K
Tornvall
Per
P
Arheden
Håkan
H
Rydén
Lars
L
Pernow
John
J
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects / Q000379:methods*; D015415:Biomarkers / Q000097:blood; D052279:Creatine Kinase, MB Form / Q000097:blood; D004562:Electrocardiography; D005260:Female; D006801:Humans; D019157:Ischemic Preconditioning, Myocardial / Q000379:methods*; D008279:Magnetic Resonance Imaging / Q000379:methods; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000473:pathology / Q000503:physiopathology / Q000628:therapy*; D015428:Myocardial Reperfusion Injury / Q000209:etiology / Q000517:prevention & control*; D011446:Prospective Studies; D013318:Stroke Volume; D020107:Troponin T / Q000097:blood
D015415:Biomarkers; D020107:Troponin T; D052279:Creatine Kinase, MB Form